CVS Health reported a 7.3% increase in total revenues to $106.1 billion for Q2 2026, with GAAP diluted EPS rising to $2.31 from $0.80 a year ago. Adjusted EPS also grew to $2.58, driven by improved margins in its Health Care Benefits segment. The company generated $10.6 billion in cash flow year-to-date and raised its full-year 2026 guidance for GAAP EPS to $6.84-$7.04 and adjusted EPS to $7.90-$8.10, reflecting strong performance across segments despite cautious outlook on costs and macro risks. CVS is expanding its healthcare services, including GLP-1 therapy support and AI-driven claims processing, aiming to enhance customer access and operational efficiency.
CVS Health reported a strong second quarter with net income soaring to $2.9 billion, nearly three times the previous year, driven by better cost control in its Aetna health plans. The medical benefits ratio improved to 87.4%, down from 89.9%, reflect...
CVS Health exceeded second-quarter earnings and revenue expectations, driven by strong performance in its insurance, pharmacy, and health services segments. The company raised its 2026 profit guidance to $7.90-$8.10 per share and revenue outlook to a...
CVS Health has revamped its weight management program to improve access to FDA-approved GLP-1 medications, including Zepbound, Foundayo, and Wegovy, through both insurance and cash-pay options. The program features a $29 online MinuteClinic visit wit...
CVS Health's AI Learning Academy received two Golds and one Silver at the 11th Annual Stevie Awards for Great Employers, recognizing excellence in employee training and workplace culture. Launched in February 2026, the program improved colleague conf...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
